Collaboration set to develop neuroinflammation therapeutics
Neuroscience company AndzonBio2 has announced it will collaborate with the University of Cambridge and Cambridge Enterprise to develop therapeutics for neuroinflammation.
The agreement states the parties will combine AndzonBio2’s expertise in early drug development and translational strategy with Cambridge’s world-leading neuroscience capabilities. This will also include the drug discovery platform developed by the university’s ALBORADA Drug Discovery Institute (ADDI).
The partnership aims to progress a novel, first-in-class therapeutic programme designed to modulate key pathways involved in neuroinflammatory processes.
“We are thrilled to enter this collaboration with the ADDI at Cambridge,” said Loic Lhuillier, CEO of AndzonBio2.
“Neuroinflammation is at the core of many severe brain diseases and new therapeutic solutions are urgently needed. By combining our complementary strengths, we have a unique opportunity to accelerate the development of a highly innovative therapeutic approach with the potential to change the treatment landscape for patients.”
“We are delighted to collaborate with AndzonBio2 on this promising project,” added Professor John Skidmore, Chief Scientific Officer of the ALBORADA Drug Discovery Institute at the University of Cambridge.
“This partnership exemplifies our commitment to translating cutting-edge neuroscience into impactful therapies. AndzonBio2 brings a focused expertise in neuroinflammation and drug development that will be instrumental in driving this promising programme forward.”
